Both earnings per share and revenue came in above Bloomberg's analyst consensus when the British-Swedish pharmaceutical giant presented its interim report on Friday.
Total revenue rose by 7 per cent to 16.2 billion dollars, while core earnings per share increased by 19 per cent in the third quarter.
Since the fourth quarter of 2025, the company has received 47 approvals in major markets, according to the report, four of which relate to entirely new medicines.
BREAKING